Alibaba
BABA
NVIDIA
NVDA
Cisco
CSCO
Netflix
NFLX
Apple
AAPL
US Stock MarketDetailed Quotes
AGEN Agenus
- 3.510
- +0.010+0.29%
Close Feb 14 16:00 ET
- 3.510
- 0.0000.00%
Post 20:01 ET
82.88MMarket Cap-0.32P/E (TTM)
3.680High3.430Low256.71KVolume3.530Open3.500Pre Close908.27KTurnover1.10%Turnover RatioLossP/E (Static)23.61MShares19.68852wk High-0.28P/B81.68MFloat Cap2.50052wk Low--Dividend TTM23.27MShs Float8419.554Historical High--Div YieldTTM7.14%Amplitude2.500Historical Low3.538Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Agenus Stock Forum
Clinical Data Alert: Agenus Unveils Dual Cancer Treatment Results for Breakthrough BOT/BAL Therapy
Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEV...
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.
These findings further reinforce the consistency of the BOT/BAL combination, which has already shown activity and ...
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
Wednesday, 29th January at 12:37 pm
Agenus Inc. (NASDAQ: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.
These...
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
Wednesday, 22nd January at 2:48 pm
• Results from two independent neoadjuvant studies in the U.S. and Europe, enrolling more than 80 patients, underscore BOT/BAL's potential to enable chemo-free and non-operative approaches in colorectal cancer (CRC).
• New randomized Phase 2 results in over 230 patients with refractory MSS mCRC, consistent with Pha...
Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
1 minute ago, 4:30 AM PST
Via BusinessWire
Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. T...
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Agenus (NASDAQ: AGEN) has secured a $22 million mortgage backed by its Berkeley and Vacaville properties, providing $20 million in net proceeds.
The two-year mortgage includes interest payable 50% in cash and 50% in common stock, at rates of 12% for Year 1 and 13% for Year 2.
The company announced a Strategic Operational Realignment Plan focusing on botensilimab/balstilimab(BOT/BAL) in MSS...
No comment yet